Räsänen JE, Neittaanmäki N, Ylitalo L, et al. - Researchers examined 5-aminolaevulinic acid nanoemulsion (BF-200 ALA) vs methyl-5-aminolaevulinate (MAL) in Daylight photodynamic therapy (DL-PDT) for grade I–II actinic keratosis (AKs) regarding the clinical efficacy, tolerability, and cost-effectiveness. In this nonsponsored, prospective randomized double-blind multicentre trial, 69 patients with 767 grade I–II AKs located symmetrically on the face or scalp were included. In a randomized split-face design, a single DL-PDT was provided. Outcomes suggest a higher efficacy of BF-200 ALA than MAL in DL-PDT for grade I–II AKs. Compared with MAL, BF-200 ALA provides slightly better value for money.